Search

Your search keyword '"Hammarin, Anna-Lena"' showing total 19 results
Start Over Author "Hammarin, Anna-Lena"
19 results on '"Hammarin, Anna-Lena"'

2. Concordance of cerebrospinal fluid real‐time quaking‐induced conversion across the European Creutzfeldt–Jakob Disease Surveillance Network

Author

McKenzie, Neil, primary, Piconi, Gabriele, additional, Culeux, Audrey, additional, Hammarin, Anna‐Lena, additional, Stergiou, Christos, additional, Tzartos, Socrates, additional, Versleijen, Alexandra A. M., additional, van de Geer, Jacqueline, additional, Cras, Patrick, additional, Cardone, Franco, additional, Ladogana, Anna, additional, Mannana, Angela, additional, Rossi, Marcello, additional, Bongianni, Matilde, additional, Perra, Daniela, additional, Regelsberger, Guenther, additional, Klotz, Sigrid, additional, Hornemann, Simone, additional, Aguzzi, Adriano, additional, Schmitz, Matthias, additional, Andrews, Mary, additional, Burns, Kimberley, additional, Haïk, Stéphane, additional, Ruiz‐García, Raquel, additional, Verner‐Carlsson, Jenny, additional, Tzartos, John, additional, Verbeek, Marcel M., additional, De Vil, Bart, additional, Poleggi, Anna, additional, Parchi, Piero, additional, Zanusso, Gianluigi, additional, Gelpi, Ellen, additional, Frontzek, Karl, additional, Reimann, Regina, additional, Hermann, Peter, additional, Zerr, Inga, additional, Pal, Suvankar, additional, and Green, Alison, additional

Published
2022
Full Text
View/download PDF

3. Concordance of CSF RT-QuIC across the European Creutzfeldt-Jakob Disease surveillance network

Author

Mckenzie, Neil, Piconi, Gabriele, Culeux, Audrey, Hammarin, Anna-Lena, Stergiou, Christos, Tzartos, Socrates, Versleijen, Alexandra A M, van de Geer, Jacqueline, Cras, Patrick, Cardone, Franco, Ladogana, Anna, Mammana, Angela, Rossi, Marcello, Bongianni, Matilde, Perra, Daniela, Regelsberger, Guenther, Klotz, Sigrid, Horneman, Simone, Aguzzi, Adriano, Matthias, Schmitz, Andrews, Mary, Burns, Kimberley, Haïk, Stéphane, Ruiz-García, Raquel, Verner-Carlsson, Jenny, Tzartos, John, Verbeek, Marcel M, De Vil, Bart, Poleggi, Anna, Parchi, Piero, Zanusso, Gianluigi, Gelpi, Ellen, Frontzek, Karl, Reiman, Regina, Hermann, Peter, Zerr, Inga, Pal, Suvankar, and Green, Alison

Subjects
prion, Cerebrospinal fluid (CSF), Real-time Quaking Induced Conversion (RT-QuIC), Creutzfeldt-Jakob disease (CJD)
Published
2022

7. Management of BK-virus infection - Swedish recommendations

Author

Dalianis, Tina, Eriksson, Britt-Marie, Felldin, Marie, Friman, Vanda, Hammarin, Anna-Lena, Herthelius, Maria, Ljungmang, Per, Molne, Johan, Wennberg, Lars, Swartling, Lisa, Dalianis, Tina, Eriksson, Britt-Marie, Felldin, Marie, Friman, Vanda, Hammarin, Anna-Lena, Herthelius, Maria, Ljungmang, Per, Molne, Johan, Wennberg, Lars, and Swartling, Lisa

Abstract

BK-virus (BKV) associated nephropathy (BKVAN) and BKV associated haemorrhagic cystitis (HC) are complications of BKV infection/reactivation in renal and allogeneic haematopoietic stem cell transplantation (HSCT) patients, respectively. The task of how to manage these diseases was given to the chair by the Swedish Reference Group for Antiviral Therapy (RAV). After individual contributions by members of the working group, consensus discussions were held in a meeting on 23 January 2018 arranged by RAV. Thereafter, the recommendations were published in Swedish on November 2018. The current translation to English has been approved by all co-authors. High BKV serum levels suggest an increased risk for BKVAN and potential graft failure. For detection of BKVAN, careful monitoring of BKV DNA levels in serum or plasma is recommended the first year after renal transplantation and when increased creatinine serum levels of unknown cause are observed. Notably, a renal biopsy is mandatory for diagnosis. To reduce the risk for progression of BKVAN, there is no specific treatment, and tailored individual decrease of immunosuppression is recommended. For BKV-HC, BKV monitoring is not recommended, since BK-viruria frequently occurs in HSCT patients and the predictive value of BKV in plasma/serum has not been determined. However, the risk for BKV-HC is higher for patients undergoing myeloablative conditioning, having an unrelated, HLA-mismatched, or a cord blood donor, and awareness of the increased risk and early intervention may benefit the patients. Also for BKV-HC, no specific therapy is available. Symptomatic treatment, e.g. forced diuresis and analgesics could be of use.

Published
2019
Full Text
View/download PDF

9. Management of BK-virus infection – Swedish recommendations

Author

Dalianis, Tina, primary, Eriksson, Britt-Marie, additional, Felldin, Marie, additional, Friman, Vanda, additional, Hammarin, Anna-Lena, additional, Herthelius, Maria, additional, Ljungman, Per, additional, Mölne, Johan, additional, Wennberg, Lars, additional, and Swartling, Lisa, additional

Published
2019
Full Text
View/download PDF

11. Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic

Author

Schmitz, Matthias, primary, Ebert, Elisabeth, additional, Stoeck, Katharina, additional, Karch, André, additional, Collins, Steven, additional, Calero, Miguel, additional, Sklaviadis, Theodor, additional, Laplanche, Jean-Louis, additional, Golanska, Ewa, additional, Baldeiras, Ines, additional, Satoh, Katsuya, additional, Sanchez-Valle, Raquel, additional, Ladogana, Anna, additional, Skinningsrud, Anders, additional, Hammarin, Anna-Lena, additional, Mitrova, Eva, additional, Llorens, Franc, additional, Kim, Yong Sun, additional, Green, Alison, additional, and Zerr, Inga, additional

Published
2015
Full Text
View/download PDF

13. Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput Method To Monitor the Humoral Immune Response against Vaccinia Virus

Author

Cosma, Antonio, primary, Bühler, Silja, additional, Nagaraj, Rashmi, additional, Staib, Caroline, additional, Hammarin, Anna-Lena, additional, Wahren, Britta, additional, Goebel, Frank D., additional, Erfle, Volker, additional, and Sutter, Gerd, additional

Published
2004
Full Text
View/download PDF

17. [New subtype of molluscipoxvirus detected].

Author

Hammarin AL, Eklund Y, Karlberg M, Bogh M, and Sikora P

Subjects
Child, Preschool, Female, Fingers virology, High-Throughput Nucleotide Sequencing, Humans, Microscopy, Electron, Molluscum contagiosum virus genetics, Sequence Analysis, DNA, Molluscum Contagiosum diagnosis, Molluscum contagiosum virus isolation & purification
Abstract

Molluscum contagiosum is a viral infection of the epidermis characterized by skin-colored papules or nodules frequently with a central depression. Atypical variants may occur, primarily in immunosuppressed individuals. We here report a case of »giant Molluscum contagiosum« in an immunocompetent child. The patient was presented with a fairly smooth nodule of 2 cm in diameter on the ring finger. Molluscipoxvirus-like virus particles were detected by electron microscopy from the nodule, but since the clinical picture was not compatible with MC, next generation sequencing was performed in order to verify the diagnosis.  Of the total number of obtained sequences, 25% belonged to molluscipoxvirus (MCV) and de novo assembly revealed three contigs corresponding to 95% of the MCV genome. The assembled genome was compared to previously published sequences of the »major envelope protein« used for genotyping of MCV genus. Several unique single nucleotide polymorphisms were identified, which led us to classify this virus as a new subtype of MCV.

Published
2016

18. [New investigations in suspected Creutzfeldt-Jakob disease. Analysis of 14-3-3 protein and T-tau in cerebrospinal fluid for safer diagnosis].

Author

Zetterberg H, Hammarin AL, Nilsson P, Andersson E, Lind B, and Blennow K

Subjects
Aged, Brain diagnostic imaging, Brain pathology, Brain physiopathology, Creutzfeldt-Jakob Syndrome diagnosis, Creutzfeldt-Jakob Syndrome pathology, Diagnosis, Differential, Fatal Outcome, Female, Humans, Male, Middle Aged, Radiography, 14-3-3 Proteins cerebrospinal fluid, Biomarkers cerebrospinal fluid, Creutzfeldt-Jakob Syndrome cerebrospinal fluid, tau Proteins cerebrospinal fluid
Abstract

Creutzfeldt-Jakob disease (CJD) is a prion disease characterized by rapid neurodegeneration that leads to the death of the patient within months to a few years. Since the disease is transmissible, there is an obligation in Sweden to report possible CJD cases to the Swedish Institute for Infectious Disease Control. To make a diagnosis of CJD is difficult, especially early in the course of the disease when the clinical features may be very vague and heterogeneous. Hence, accurate biological markers both for confirming and excluding CJD would be of great value. The currently recommended investigation of a patient with possible CJD comprises clinical evaluation. electroencephalography, computed tomography or magnetic resonance imaging of the brain and test for 14-3-3 protein in the cerebrospinal fluid (CSF). Recent studies suggest that analysis of total tau (T-tau) and phospho-tau (P-tau) in CSF is a valuable complement to this set of investigations. Here, we review how CSF T-tau and P-tau may aid in the diagnosis of CJD and illustrate this by presenting cases from routine clinical practice.

Published
2005

19. Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.

Author

Cosma A, Bühler S, Nagaraj R, Staib C, Hammarin AL, Wahren B, Goebel FD, Erfle V, and Sutter G

Subjects
Animals, Antibodies, Viral analysis, Antibodies, Viral blood, Antibody Formation, Antibody Specificity, B-Lymphocytes cytology, Cell Line, Genetic Vectors, Green Fluorescent Proteins, Humans, Luminescent Proteins genetics, Mice, Rabbits, Neutralization Tests methods, Vaccinia immunology, Vaccinia virus genetics, Vaccinia virus immunology
Abstract

Vaccination against smallpox is again considered in order to face a possible bioterrorist threat, but the nature and the level of the immune response needed to protect a person from smallpox after vaccination are not totally understood. Therefore, simple, rapid, and accurate assays to evaluate the immune response to vaccinia virus need to be developed. Neutralization assays are usually considered good predictors of vaccine efficacy and more informative with regard to protection than binding assays. Currently, the presence of neutralizing antibodies to vaccinia virus is measured using a plaque reduction neutralization test, but this method is time-consuming and labor-intensive and has a subjective readout. Here, we describe an innovative neutralization assay based on a modified vaccinia virus Ankara (MVA) vector expressing the green fluorescent protein (MVA-gfp). This MVA-gfp neutralization assay is rapid and sensitive and has a high-throughput potential. Thus, it is suitable to monitor the immune response and eventually the efficacy of a large campaign of vaccination against smallpox and to study the vector-specific immune response in clinical trials that use genetically engineered vaccinia viruses. Most importantly, application of the highly attenuated MVA eliminates the safety concern in using the replication-competent vaccinia virus in the standard clinical laboratory.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results